Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers
NCT07729917Phase 2Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial in biliary tract cancer (BTC) and cholangiocarcinoma (CCA) (8 arms), sponsored by Zhejiang University. Primary endpoint: Objective Response Rate up to 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
biliary tract cancer (BTC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07729917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729917.